What Is the Best Treatment for Rheumatoid Arthritis?

The best treatment for rheumatoid arthritis depends on when the disease is caught, how severe it is, and how your body responds to initial therapy. For most people, treatment begins with methotrexate under a “treat-to-target” strategy that adjusts medications at regular intervals until inflammation is driven as low as possible. That approach, combined with biologic and targeted therapies for those who need escalation, has made disease remission a realistic outcome rather than a rare exception.

Why Methotrexate Comes First

Methotrexate has been the cornerstone of rheumatoid arthritis treatment for decades, and not because nothing better has come along. It works well enough in a large share of patients, it’s inexpensive, it’s available in both pill and injectable form, and doctors have a deep understanding of its long-term safety profile. Newer therapies are typically added to methotrexate rather than replacing it, because the combination tends to outperform either alone.

The idea behind treat-to-target is simple: set a measurable goal for disease activity (usually remission or near-remission), check progress every few months, and change therapy if you’re not getting there. A Dutch cohort study following patients with very early rheumatoid arthritis under this approach found that about half achieved remission within six months, and that number climbed to nearly 60% by one year, with most patients showing no meaningful joint damage on imaging.¹ A separate comparative study found that patients managed with treat-to-target reached remission at nearly 50% higher rates than those receiving routine care after two years.²

The takeaway: it’s not just the drug that matters, it’s the discipline of the monitoring system around it. A perfectly good medication prescribed in a wait-and-see fashion will underperform the same medication prescribed with regular dose checks and escalation rules.

Starting With Combination DMARDs or Going Solo

One question doctors weigh early on is whether to begin with methotrexate alone or combine it with other conventional disease-modifying drugs from the start. The tREACH trial randomized patients with recent-onset rheumatoid arthritis to either triple therapy (methotrexate plus two other older DMARDs) or methotrexate alone. After three months, disease activity scores were lower in the combination group, and those patients needed biologic therapy at half the rate of the methotrexate-only patients.³ At one year, the combination group still required fewer treatment intensifications to stay on target, though joint damage on X-rays was similar between the groups.⁴

In practice, many rheumatologists still start with methotrexate alone and escalate quickly if the response isn’t adequate. Others, particularly when disease activity is high at diagnosis, prefer to hit hard early with combination therapy. Both approaches are supported by guidelines, and neither is clearly wrong.

Short-Term Glucocorticoids as a Bridge

Methotrexate and other DMARDs take weeks to months to reach their full effect, so doctors commonly prescribe a short course of low-dose glucocorticoids (like prednisone) to control inflammation while the DMARDs ramp up. European guidelines endorse this “bridging” strategy for the first weeks to months of treatment. A review of steroid use in rheumatoid arthritis concluded that low-dose glucocorticoids during the first two years of disease appear reasonably safe, partly because controlling inflammation itself reduces harm to bones and blood vessels.⁵ The key word is “low-dose” and “short-term.” Long-term steroid use at higher doses creates a cascade of problems, from bone loss to blood sugar spikes, that you want to avoid.

NSAIDs like ibuprofen and naproxen also help with stiffness and pain, but they don’t slow the disease itself. They’re symptom relievers, not disease modifiers, which is an important distinction. You can feel better on NSAIDs while joint damage silently progresses.

Biologic Therapies

When methotrexate alone or in combination with conventional DMARDs doesn’t get the job done, the next step is typically adding a biologic therapy. These are engineered proteins that target specific pieces of the immune system driving joint inflammation. The most commonly used class blocks a molecule called TNF, and several TNF-blocking drugs are available. Other biologics target different immune pathways: one blocks the communication between immune cells (abatacept), another depletes a type of immune cell called B cells (rituximab), and yet another blocks an inflammatory signaling molecule called interleukin-6 (tocilizumab).

A reasonable question is whether one biologic is clearly better than the others. The short answer is no. Head-to-head trials comparing biologics with different mechanisms of action have found broadly similar rates of clinical improvement. In one trial, abatacept and adalimumab (a TNF inhibitor) produced nearly identical response rates of about 64% and 63%, respectively. Indirect comparisons across trials point in the same direction: when combined with methotrexate, the approved biologics perform similarly.⁶ This means the choice often comes down to factors beyond pure efficacy: your other health conditions, your comfort with injections versus infusions, your insurance coverage, and your doctor’s experience with a given drug.

JAK Inhibitors and the Oral Option

A newer class of drugs called JAK inhibitors (tofacitinib, baricitinib, upadacitinib) arrived as the first oral targeted therapies for rheumatoid arthritis, offering an alternative to injected or infused biologics. In terms of effectiveness, a meta-analysis comparing JAK inhibitors with TNF inhibitors found that JAK inhibitors produced a small but meaningful improvement in physical function scores and were at least as effective at reducing disease activity.⁷

The tradeoff involves safety, specifically blood clots. A large meta-analysis found that JAK inhibitors carry a roughly 30% higher risk of venous thromboembolism compared with TNF inhibitors in rheumatoid arthritis patients.⁸ For serious infections, cancer, and major heart events, the two classes looked comparable. That blood clot signal, though, means doctors tend to be more cautious about prescribing JAK inhibitors to people with existing risk factors for clots, including older adults, smokers, and those with a history of clotting disorders.

When a Treatment Stops Working

Roughly a third of patients on any given biologic will eventually lose their response or never respond adequately in the first place. At that point, the main strategic decision is whether to try another drug in the same class (called cycling) or switch to a drug with an entirely different mechanism (called swapping). If you’re on a TNF inhibitor that has stopped working, for instance, your doctor might try a different TNF inhibitor or move to a non-TNF biologic like rituximab or abatacept.⁹

Evidence on which strategy is better isn’t fully settled. If the first TNF inhibitor failed because of side effects rather than lack of efficacy, cycling to a second TNF inhibitor often works. If the drug simply stopped controlling the disease over time, swapping to a different mechanism may give you a better shot. This is one of those areas where clinical judgment and your individual history carry a lot of weight.

Can You Taper or Stop Medication After Remission?

Once someone reaches sustained remission, the natural question is whether they can safely reduce or stop their medication. The answer is: sometimes, but the odds of relapse are real. In the RETRO trial, patients in stable remission were randomly assigned to continue full-dose therapy, taper to half dose, or stop entirely. At 12 months, about 81% of those who continued their medication stayed in remission, compared with roughly 59% of those who tapered and 43% of those who stopped.¹⁰ On the reassuring side, most patients who relapsed after tapering regained remission once they went back to their full dose.

A newer concept gaining traction is “clinical deep remission,” meaning not just meeting the standard remission threshold but being well below it, with virtually no detectable disease activity. A study found that patients in deep remission tolerated tapering far better: the increased relapse risk from dose reduction was dramatically lower in this group compared with those who met standard remission criteria but still had some residual disease activity.¹¹ A separate retrospective study found that whether you taper gradually or stop abruptly didn’t significantly change the relapse rate, suggesting that the underlying immunologic stability of the remission matters more than how you withdraw the drug.¹²

Exercise as a Treatment Complement

There’s a persistent worry that vigorous exercise will worsen rheumatoid arthritis. The evidence says the opposite. A Cochrane review of dynamic exercise therapy found it improves aerobic fitness and muscle strength without worsening disease activity or pain.¹³ A two-year randomized trial of high-intensity exercise in rheumatoid arthritis patients confirmed these findings: the exercise group gained better physical function and emotional well-being, and their disease activity didn’t increase. Joint damage in large joints didn’t progress in either group, though patients who started with substantial existing joint damage showed slightly more progression if they exercised intensely.¹⁴

A large umbrella review of meta-analyses found that exercise significantly reduced pain, fatigue, and disease activity scores in people with rheumatoid arthritis, as well as lowering inflammatory markers in the blood.¹⁵ Exercise isn’t a replacement for medication, but it’s one of the most consistently helpful add-ons, and one of the few interventions with essentially no downside when done sensibly.

Omega-3 Fatty Acids and Diet

Among dietary supplements, omega-3 fatty acids (found in fish oil) have the strongest evidence base for rheumatoid arthritis. Clinical studies show they can reduce the number of swollen and tender joints and modulate disease activity.¹⁶ An umbrella review combining evidence from multiple analysis methods concluded that omega-3 fatty acids have a genuinely beneficial effect on rheumatoid arthritis, reducing disease risk, activity, and inflammatory markers.¹⁷ The effects are modest compared to prescription medications, but as a low-risk addition to standard therapy, omega-3s are one of the few supplements worth discussing with your doctor.

Heart Health and Treatment Choices

Rheumatoid arthritis substantially raises cardiovascular risk, largely because the chronic inflammation that damages joints also damages blood vessels. This makes treatment choices a cardiovascular decision, not just an arthritis decision. A large systematic review found that patients on conventional DMARDs without a biologic had a higher risk of major heart events and stroke compared with those on TNF inhibitors.¹⁸ Among biologics, tocilizumab was associated with a lower risk of major heart events than TNF inhibitors, while abatacept showed no significant difference from TNF inhibitors.

A separate study using coronary imaging found that biologic use was associated with substantially lower long-term cardiovascular risk, potentially by stabilizing the type of arterial plaque most likely to rupture and cause a heart attack.¹⁹ The picture isn’t entirely one-sided, though: a meta-analysis noted that biologic treatment was associated with a slight increase in carotid artery wall thickness, a marker of atherosclerosis.²⁰ The net effect still appears cardiovascularly favorable, but it underscores why monitoring heart risk factors remains important even on effective therapy.

Treatment Decisions in Pregnancy and Lung Disease

Two situations that complicate treatment decisions deserve attention. In pregnancy, certain biologics like adalimumab, infliximab, and golimumab are conditionally recommended through the first half of pregnancy but are generally discontinued in the third trimester to minimize drug exposure to the newborn.²¹ Planning ahead with your rheumatologist is critical, because disease flares during pregnancy are common when medications are stopped abruptly without a transition plan.

For patients with rheumatoid arthritis-associated interstitial lung disease, treatment choices shift. Methotrexate was historically avoided in these patients due to concern about lung toxicity, though recent guidelines have softened that stance: mild, stable lung disease is no longer considered an automatic reason to withhold methotrexate. Among biologics, abatacept and rituximab tend to be favored for patients with significant lung involvement, while the evidence on TNF inhibitors, IL-6 blockers, and JAK inhibitors in this context is less settled. The decision should ideally involve both a rheumatologist and a pulmonologist.²²

Biosimilars and the Cost Barrier

Biologic therapies are expensive, and for many patients cost is a decisive factor. Biosimilars, which are near-identical copies of originator biologics produced once patents expire, have made these treatments more accessible. A systematic review of 24 randomized trials covering over 10,000 patients found that biosimilars met strict equivalence standards with their reference biologics for both clinical response rates and functional improvement.²³ A real-world monitoring study tracking patients over four years confirmed that disease activity levels were indistinguishable between those taking biosimilar and originator versions of etanercept and adalimumab.²⁴

If you’re prescribed a biologic and are concerned about cost, asking whether a biosimilar version is available is a reasonable conversation to have. In some countries, switching to biosimilars has been driven by national health policy; in others, it’s a patient-by-patient discussion.

What Patients Actually Want From Treatment

Researchers have spent time asking patients what they value most in their treatment, and the answers might surprise clinicians. A conjoint analysis study found that route of administration ranked as the single most important treatment attribute for patients, more important than side effects, cost, or even pain reduction. Over half of respondents preferred an oral medication.²⁵ A large international survey confirmed that about 60% of patients preferred oral medications and that more than 70% wanted a rapid onset of action.²⁶ This preference partly explains the enthusiasm around JAK inhibitors, which are taken as pills. It also highlights a tension in treatment: the most effective option on paper isn’t always the one a patient will actually take consistently.

Toward Precision Medicine and Biomarkers

One of the frustrations in rheumatoid arthritis treatment is the trial-and-error approach to finding the right drug. Research is slowly moving toward using blood-based biomarkers to predict who will respond to what. Rheumatoid factor and anti-citrullinated protein antibodies (anti-CCP) may help guide the order in which biologics are tried.²⁷ For example, patients who are positive for these antibodies and who have low B-cell counts in their joint tissue tend to respond better to rituximab, which depletes B cells.²⁸

More recently, a study found that high baseline levels of the anti-inflammatory molecule interleukin-10 predicted a better response to abatacept in early rheumatoid arthritis, including less bone erosion.²⁹ None of these biomarkers is reliable enough yet to serve as a standalone decision tool, but they represent a future where treatment selection is guided by biology rather than trial and error.

Vagus Nerve Stimulation

Among genuinely novel approaches, vagus nerve stimulation stands out. The vagus nerve is part of a circuit that naturally helps regulate inflammation, and small pilot studies have tested whether electrically stimulating it with an implanted device can reduce rheumatoid arthritis symptoms. In one study of patients with drug-refractory disease, stimulating the vagus nerve up to four times daily significantly reduced TNF (a key inflammatory molecule) and improved standard clinical scores over 84 days.³⁰ A later pilot study of a miniaturized device confirmed safety and showed reduced symptoms in patients who had failed multiple drugs.³¹ This is still early-stage research with small numbers, but a device-based treatment that works through the nervous system rather than the immune system would be fundamentally different from anything currently available.

The Oral-Gut-Joint Connection

An emerging and somewhat surprising line of research links periodontal (gum) disease to rheumatoid arthritis through the gut microbiome. A study of female rheumatoid arthritis patients found that a specific oral bacterium, Porphyromonas, was present in higher amounts in those with both gum disease and active rheumatoid arthritis, and its levels correlated with both periodontal and rheumatologic measurements.³² An animal study pushed this further, showing that transplanting gum disease-associated bacteria into the guts of arthritis-prone mice worsened their joint inflammation, disrupted the intestinal barrier, and shifted their immune balance toward a more inflammatory state.³³

This research is still working out the details of how oral bacteria reach the gut and alter immune function in a way that affects joints. But it adds weight to the practical advice that good dental hygiene may matter more for rheumatoid arthritis patients than previously appreciated. Treating gum disease won’t replace methotrexate, but ignoring it could quietly undermine the therapies that are working.

Vaccinations and Immune-Suppressing Treatment

Because most rheumatoid arthritis medications suppress parts of the immune system, vaccination strategy needs some thought. Live vaccines, like the older shingles vaccine, should ideally be given at least four weeks before starting biologic or targeted synthetic therapies, since the suppressed immune system may not handle a live virus safely. The newer non-live shingles vaccine avoids this problem, but timing conversations with your rheumatologist still matter for optimal immune response.³⁴ Flu and pneumonia vaccines are generally safe and recommended on treatment, though their effectiveness may be slightly blunted. The practical point is straightforward: get vaccinated, but coordinate the timing with your treatment schedule rather than skipping shots altogether.